Authored By: Sarah
21 Dec 2022

Multiple Myeloma Drugs Market Share will Witness a YOY Growth Rate of 5.76% in 2023 

The multiple myeloma drugs market share is forecast to reach USD 6,419.94 million, after growing at a CAGR of 5.9% during 2023-2027. The growing incidence of multiple myeloma is analyzed to boost the addictions therapeutics market growth. Moreover, emergence of nanomedicine platforms is the major trend enhancing the overall market demand for multiple myeloma drugs during the forecast period.   

Get a snapshot on the multiple myeloma drugs market analysis: Unlock the Sample Report 

Multiple Myeloma Drugs Market Share will Witness a YOY Growth Rate of 5.76% in 2023

Technavio’s report on: “Multiple Myeloma Drugs Market by Therapy, Distribution channel, and Geography - Forecast and Analysis 2023-2027" covers an in-depth analysis of the following segments of the market. 

Therapy : 

  • Targeted therapy: The multiple myeloma drugs market growth by the Targeted therapy will be significant during the forecast period.  recent drug approvals are showing impressive sales growth, which represents the continued strong adoption of proteasome inhibitors for the treatment of multiple myeloma. 

  • Biologic therapy

  • Chemotherapy

  • Others 

Geography: 

  • North America: North America is expected to benefit significantly from the heavy sales of approved myeloma drugs in the region for its treatment. North America will contribute 36% of market growth by 2027. 

  • Europe 

  • APAC

  • Rest of World (ROW) 

Distribution channel: 

  • Hospital pharmacy 

  • Retail pharmacy

  • E-pharmacy

Key Takeaways: 

  • The multiple myeloma drugs market size will witness a YOY Growth Rate of 5.76% in 2023.  

  • The growing popularity of complementary and alternative medicine will be a major challenge for the multiple myeloma drugs market during the forecast period. 

  • Major key multiple myeloma drugs market players include: Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca Plc, Bristol Myers Squibb Co., Cipla Ltd., Daiichi Sankyo Co. Ltd., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, GlaxoSmithKline Plc, Johnson and Johnson, Merck and Co. Inc., Novartis AG, Pfizer Inc., PharmaMar SA, Sanofi SA, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.  

  • The report illustrates the lifecycle of the market, focusing on the adoption rates of the major regions such as the North America, Europe, Asia, and Rest of World (ROW). 

Download the PDF sample report for highlights on the market size, growth momentum, regional growth opportunities, vendor analysis, and other factors influencing the market growth. 

Key data covered in the Multiple Myeloma Drugs Market report 

  • Precise market size estimation during the forecast period 2023-2027.  

  • CAGR of the multiple myeloma drugs market forecast during 2023-2027.  

  • Market-level data on units, average selling prices, and values of the multiple myeloma drugs market share.  

  • Prediction of the upcoming trends, drivers, and factors that challenge the growth of the multiple myeloma drugs market.  

  • Multiple myeloma drugs industry growth across North America, Europe, Asia, and Rest of World (ROW).

Read News Read Less
Interested in this report?
Get your sample now!
Technavio